The Vanderbilt Eye Institute (VEI) recently hosted the Southeastern Vision Conference to celebrate and share excellence in vision science.

Vision science at Vanderbilt has experienced tremendous growth in recent years.

Understanding how the protein TRPV1 helps neurons survive after glaucoma-related stressors could lead to new therapeutic strategies for glaucoma and other neurodegenerative conditions.

Vanderbilt University has launched a regenerative visual neuroscience initiative to develop new ways of treating — and restoring sight to — people who have been blinded by glaucoma, macular degeneration, diabetic retinopathy and eye injuries.

An ion channel protein called TRIPV1 helps retinal neurons survive the elevated eye pressure associated with glaucoma.

Three years ago, a team of researchers led by David Calkins, Ph.D., vice chair and director of Research at the Vanderbilt Eye Institute, showed that the first sign of injury in glaucoma, the leading cause of blindness in the United States, occurs in the brain.

David Calkins, Ph.D., vice chair and director of Research for the Vanderbilt Eye Institute, was recently awarded a Research to Prevent Blindness (RPB) Senior Scientific Investigator Award.